NADA MOHAMED ALI ANWAR MOHAMED ELHOFFY

06/12/2023

https://www.mdpi.com/1999-4923/15/12/2734

NADA MOHAMED ALI ANWAR MOHAMED ELHOFFY

Magdy Ibrahim; Nermin Eissa

23/10/2023

https://www.mdpi.com/1999-4923/15/10/2513

NADA MOHAMED ALI ANWAR MOHAMED ELHOFFY

Mohammed Abdallah Ahmed, Nadia M. Morsi

15/11/2022

https://www.tandfonline.com/doi/full/10.1080/10717544.2022.2144546

NADA MOHAMED ALI ANWAR MOHAMED ELHOFFY

Mona M. AbouSamra, Nahla A. El-Wakil, Ghada E. A. Awad, Rabab Kamel

16/09/2022

https://www.mdpi.com/2310-2861/8/9/593

NADA MOHAMED ALI ANWAR MOHAMED ELHOFFY

Nermeen El Kasabgy

15/07/2022

https://www.tandfonline.com/doi/full/10.1080/10717544.2022.2092239

NADA MOHAMED ALI ANWAR MOHAMED ELHOFFY

Seham A Elkheshen ; Rania M Hathout; Marwa A Fouly

25/06/2022

https://www.dovepress.com/augmented-in-vitro-and-in-vivo-profiles-of-brimonidine-tartrate-using--peer-reviewed-fulltext-article-IJN

NADA MOHAMED ALI ANWAR MOHAMED ELHOFFY

18/05/2022

https://fjps.springeropen.com/articles/10.1186/s43094-022-00417-5

NADA MOHAMED ALI ANWAR MOHAMED ELHOFFY

Magdy Ibrahim

09/05/2022

https://www.tandfonline.com/doi/full/10.1080/10717544.2022.2069882

NADA MOHAMED ALI ANWAR MOHAMED ELHOFFY

Elkheshen SA; Kamel AO; Nasr M, Moftah NH; Ragai MH; Elezaby RS

13/04/2022

https://www.tandfonline.com/doi/full/10.1080/10717544.2022.2058652

NADA MOHAMED ALI ANWAR MOHAMED ELHOFFY

22/02/2022

https://www.mdpi.com/1999-4923/14/3/470

NADA MOHAMED ALI ANWAR MOHAMED ELHOFFY

Nada M El Hoffy, Engy A Abdel Azim, Rania M Hathout, Marwa A Fouly, Seham A Elkheshen

01/11/2020

Glaucoma, being asymptomatic for relatively late stage, is recognized as a worldwide cause of irreversible vision loss. The eye is an impervious organ that exhibits natural anatomical and physiological barriers which renders the design of an efficient ocular delivery system a formidable task and challenge scientists to find alternative formulation approaches. In the field of glaucoma treatment, smart delivery systems for targeting have aroused interest in the topical ocular delivery field owing to its potentiality to oppress many treatment challenges associated with many of glaucoma types. The current momentum of nano-pharmaceuticals, in the development of advanced drug delivery systems, hold promises for much improved therapies for glaucoma to reduce its impact on vision loss. In this review, a brief about glaucoma; its etiology, predisposing factors and different treatment modalities has been reviewed. The diverse ocular drug delivery systems currently available or under investigations have been presented. Additionally, future foreseeing of new drug delivery systems that may represent potential means for more efficient glaucoma management are overviewed. Finally, a gab-analysis for the required investigation to pave the road for commercialization of ocular novel-delivery systems based on the nano-technology are discussed.

NADA MOHAMED ALI ANWAR MOHAMED ELHOFFY

Hussein O Ammar, Magdy Ibrahim, Azza A Mahmoud, Rehab N Shamma, Nada M El Hoffy

01/11/2020

Purpose: In this study, the preparation of self-assembled polymer-free in situ forming nanovesicles (ISNs) based on non-ionic surfactants (NISs) is presented.Methods: A 22·41 full factorial experimental design was adopted for the development of novel polymer-free ISNs loaded with tenoxicam utilizing the emulsion method. The type of NIS (Brij® 52 or Span® 60), the cholesterol percentage (30, 50, or 60 w/w%), and the internal phase percentage (20 or 30 v/v%) were chosen as the independent variables. Percentage drug released after 1 h (Q1), vesicle particle size (PS), and mean dissolution time (MDT) were the dependent variables. Selected formulation was investigated morphologically using transmission electron microscopy. Results: Results revealed that the formation had spherical dense shape. All independent factors significantly affected the percentage drug release after the first hour (Q1), and the MDT, while only the type of NIS had a significant effect on PS. The highest control of drug release was observed in formulation containing Span® 60 with lower internal phase percentage (MDT = 20.06 ± 0.40 h) as well as the smallest PS (123.75 ± 16.68 nm).Conclusion: The obtained results indicated the potentiality of the invented ISNs in controlling the release of tenoxicam in a desirable economical biphasic pattern compared to other in situ formulations.

NADA MOHAMED ALI ANWAR MOHAMED ELHOFFY

Shymaa Hatem, Nada M El Hoffy, Reham S Elezaby, Maha Nasr, Amany O Kamel, Seham A Elkheshen

01/08/2020

"Extensive melanin production and accumulation inside the skin may result in a number of disorders, among which is acquired hyperpigmentation, such as melasma. Skin hyperpigmentation is attributed to either the increase in the number of melanocytes or the hyperactivity of melanogenic enzymes. Genetic susceptibility, ultraviolet radiation, hormonal remedies as well as the abnormal release of the α-melanocyte stimulating hormone (α-MSH) represent the provoking factors contributing to such disorder. On the account of their prominent localization in skin-exposed areas, hyperpigmentation may possess cosmetic and psychosocial relevance, and subsequently many efforts have been exerted to help rectify this skin disorder. The current review presents the approaches adopted to treat melasma. It also reviews the active molecules counteracting the melanogenesis process and the diverse nanotechnology-based delivery systems, which showed successful topical delivery of hypopigmenting agents for the treatment of melasma. 1"

NADA MOHAMED ALI ANWAR MOHAMED ELHOFFY

M. Haider , M. Ibrahim

01/02/2017

Diltiazem hydrochloride (DTZ) is a calcium channel antagonist depicted by extensive first pass metabolism and low oral bioavailability. The aim of this work was to develop niosomes for potential nasal delivery of DTZ. Niosomes protect hydrophilic drugs inside their core while nasal route offers both rapid onset and evasion of first-pass metabolism. Niosomes were prepared using a combination of Span 60 or Brij-52 with cholesterol (CHOL) in different molar ratios followed by determination of entrapment efficiency, particle size and in vitro drug release. A parallel design was adopted to evaluate the pharmacokinetic performance of DTZ-loaded niosomes in male Wistar rats. Non-compartmental analysis was performed where Cmax, Tmax, t1/2, MRT, area under the release curve (AUC) and Ke were assessed. The prepared niosomes were spherical with mean particle size 0.82–1.59 μm. Span 60-cholesterol niosomes (1:1 molar ratio) showed the highest entrapment and release efficiencies. In vivo study revealed an increase in MRT, t1/2 and AUC with a decrease in Ke. In conclusion, nasal niosomal formulation of DTZ expressed suitable pharmacokinetic parameters and bioavailability through prolonged duration of action inside the body as well as low rate of elimination depicting a promising alternate to the conventional oral route.